EUVIMEDEUVIMED entdecken
Crossref

A Single-Arm, Low-Dose, Prospective Study of 177 Lu-EB-PSMA Radioligand Therapy in Patients with Metastatic Castration-Resistant Prostate Cancer

Guochang Wang, Jie Zang, Yuanyuan Jiang, Qingxing Liu, Huimin Sui, Rongxi Wang, Xinrong Fan, Jingjing Zhang, Zhaohui Zhu, Xiaoyuan Chen

Journal of Nuclear Medicine · 2023-04 · 64 (4) · 611-617

DOI: 10.2967/jnumed.122.264857 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Nuclear Medicine, online erschienen am 03.11.2022. Verfasst von Guochang Wang und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nuclear Medicine, State Key Laboratory of Complex Severe and Rare Diseases, Beijing Key Laboratory of Molecular Targeted Diagnosis and …. Hauptthemen laut MEDLINE: Prostate-Specific Antigen, Prostatic Neoplasms, Castration-Resistant. Die Arbeit wurde bisher 31-mal zitiert (Crossref) und nennt 35 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

We aimed to investigate the safety and therapeutic efficacy of radioligand therapy (RLT) of 177Lu-EB-prostate-specific membrane antigen (PSMA) in patients with metastatic castration-resistant prostate cancer.

Methods

Thirty men with progressive metastatic castration-resistant prostate cancer previously treated with taxane-based chemotherapy and second-generation androgen deprivation therapy were enrolled. All patients received up to 3 cycles of approximately 2.0 GBq (55 mCi) of 177Lu-EB-PSMA per cycle at 8-wk intervals. The primary endpoint was therapeutic safety, including changes in hematologic status, liver function, and renal function. An additional primary endpoint was therapeutic efficacy, including prostate-specific antigen (PSA) response and molecular imaging response. The secondary endpoints were PSA progression-free survival (PFS) and overall survival (OS). Another endpoint was patient-reported health-related quality of life.

Results

From January 2019 to December 2021, 30, 22, and 11 patients received 1, 2, or 3 cycles of 177Lu-EB-PSMA RLT, respectively. During the entire follow-up period, 33.3% of patients experienced grade 3 hematologic adverse events. Seventeen (56.7%) patients achieved a PSA reduction of at least 50%. The median PSA PFS was 4.6 mo (95% CI, 2.7-6.5 mo), and the median OS was 12.6 mo (95% CI, 8.1-17.1 mo). A higher whole-body PSMA SUVmean correlated with a better PSA response, higher baseline alkaline phosphatase and larger total PSMA-positive tumor volume were associated with worse PSA PFS, and the existence of visceral metastases and higher PSA value at baseline were significant prognosticators of worse OS. Health-related quality-of-life outcomes improved significantly after 177Lu-EB-PSMA RLT.

Conclusion

RLT based on approximately 2.0 GBq of 177Lu-EB-PSMA for up to 3 cycles may achieve a PSA response and hematologic toxicity comparable to those from 7.4-GBq doses of 177Lu-PSMA-617 for up to 4-6 cycles. Further studies with more cycles of 177Lu-EB-PSMA RLT are needed to evaluate the potential benefits in terms of PFS and OS.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Prostate-Specific AntigenProstatic Neoplasms, Castration-ResistantMaleHumansProspective StudiesQuality of LifeAndrogen AntagonistsTreatment OutcomeDipeptidesHeterocyclic Compounds, 1-RingLutetiumRetrospective Studies

Stichwörter der Autor:innen

177Lu-EB-PSMAEvans bluealbumin bindingmetastatic castration-resistant prostate cancer (mCRPC)radioligand therapy

Substanzen

Prostate-Specific AntigenAndrogen AntagonistsDipeptidesHeterocyclic Compounds, 1-RingLutetium

Autor:innen und Institutionen

  • Department of Nuclear Medicine, State Key Laboratory of Complex Severe and Rare Diseases, Beijing Key Laboratory of Molecular Targeted Diagnosis and Therapy in Nuclear Medicine, Peking Union Medical College Hospital, Ch…
  • Department of Nuclear Medicine, First Affiliated Hospital, Fujian Medical University, Fuzhou, China.
  • Department of Urology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Peking Union Medical College, Beijing, China.
  • Departments of Diagnostic Radiology, Surgery, Chemical Engineering, Biomolecular Engineering, and Biomedical Engineering, Yong Loo Lin School of Medicine and College of Design and Engineering, National University of Sin…
  • Clinical Imaging Research Centre, Centre for Translational Medicine, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore.
  • Nanomedicine Translational Research Program, NUS Center for Nanomedicine, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore; and.

Zitieren

APA

Wang, G., Zang, J., Jiang, Y., Liu, Q., Sui, H., Wang, R., Fan, X., Zhang, J., Zhu, Z., & Chen, X. (2023). A Single-Arm, Low-Dose, Prospective Study of 177 Lu-EB-PSMA Radioligand Therapy in Patients with Metastatic Castration-Resistant Prostate Cancer. Journal of Nuclear Medicine, 64(4), 611-617. https://doi.org/10.2967/jnumed.122.264857

Vancouver

Wang G, Zang J, Jiang Y, Liu Q, Sui H, Wang R, et al. A Single-Arm, Low-Dose, Prospective Study of 177 Lu-EB-PSMA Radioligand Therapy in Patients with Metastatic Castration-Resistant Prostate Cancer. Journal of Nuclear Medicine. 2023;64(4):611-617. doi:10.2967/jnumed.122.264857

BibTeX
@article{Wang2023,
  author = {Wang, Guochang and Zang, Jie and Jiang, Yuanyuan and Liu, Qingxing and Sui, Huimin and Wang, Rongxi and Fan, Xinrong and Zhang, Jingjing and Zhu, Zhaohui and Chen, Xiaoyuan},
  title = {A Single-Arm, Low-Dose, Prospective Study of 177 Lu-EB-PSMA Radioligand Therapy in Patients with Metastatic Castration-Resistant Prostate Cancer},
  journal = {Journal of Nuclear Medicine},
  year = {2023},
  volume = {64},
  number = {4},
  pages = {611--617},
  doi = {10.2967/jnumed.122.264857}
}
Kostenlos starten →